Document is current
Any future updates will be listed below
-
Authors
Dollfus, Hélène http://orcid.org/0000-0002-2249-895X
Lilien, Marc R. http://orcid.org/0000-0002-8956-0324
Maffei, Pietro
Verloes, Alain http://orcid.org/0000-0003-4819-0264
Muller, Jean http://orcid.org/0000-0002-7682-559X
Bacci, Giacomo M. http://orcid.org/0000-0002-8741-4833
Cetiner, Metin http://orcid.org/0000-0002-0918-9204
van den Akker, Erica L. T. http://orcid.org/0000-0001-5352-9328
Grudzinska Pechhacker, Monika
Testa, Francesco
Lacombe, Didier
Stokman, Marijn F.
Simonelli, Francesca
Gouronc, Aurélie http://orcid.org/0000-0003-0758-8882
Gavard, Amélie
van Haelst, Mieke M. http://orcid.org/0000-0002-7519-0246
Koenig, Jens http://orcid.org/0000-0002-9732-8656
Rossignol, Sylvie
Bergmann, Carsten
Zacchia, Miriam
Leroy, Bart P. http://orcid.org/0000-0002-9899-2081
Mosbah, Héléna
Van Eerde, Albertien M. http://orcid.org/0000-0001-5953-5956
Mekahli, Djalila http://orcid.org/0000-0003-0954-6088
Servais, Aude
Poitou, Christine
Valverde, Diana http://orcid.org/0000-0002-7024-1657
- License Information
-
More Information
Article History
Received: 13 December 2023
Revised: 15 March 2024
Accepted: 9 May 2024
First Online: 31 July 2024
Competing interests
: The development of this work was made without external financial support from industries involved in the manufacturing of therapies for BBS. Competing interests of members of the guideline development group have been recorded in writing and addressed. HD has consulted for Novartis, Rhythm Pharmaceuticals, Jansen Pharmaceutical, GenSight Biologics and Sparing Vision. JK, DL, AG, MMVH and JM have consulted for Rhythm Pharmaceuticals. EVDA’s institute was the recipient of a research grant from Rhythm Pharmaceuticals. MC is a principal investigator for the RM-IMC-901 study (a Registry of Patients with Biallelic Proopiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1), or Leptin Receptor (LEPR) Deficiency Obesity, or Bardet-Biedl Syndrome (BBS), Treated with Setmelanotide) and received payments for lectures, expert testimony and consulting fees and study support from Rhythm Pharmaceuticals; MC also received payments for lectures from Canon Medical Systems. CB is the medical and managing director of Medizinische Genetik Mainz and Limbach Genetics. BPL has consulted for Novartis, Jansen Pharmaceutical, GenSight Biologics and Sparing Vision. CP has consulted for Rhythm Pharmaceuticals and Novo Nordisk. SR has consulted for Rhythm Pharmaceuticals, Sandoz and Novo Nordisk. MRL, PM, AV, GMB, MGP, FT, MFS, FS, AG, MZ, HM, AMVE, DM, AS, DV, have no competing interests to declare.
